Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in IBS-D
2013-002394-22Phase 3Terminated
- Sponsor
- Salix Pharmaceuticals, Inc.
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rifaximin in Diarrhea-predominant irritable bowel syndrome (IBS-D), sponsored by Salix Pharmaceuticals, Inc. Primary endpoints: Primary efficacy endpoint and Safety endpoint. Started Jul 2013; status: terminated.
02
Drugs
rifaximin
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on 2013-002394-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002394-22.